Taysha Gene Therapies, Inc. (TSHA)

2.3000 -0.0500 (-2.13%) At close: 04:00PM EDT

Taysha Gene Therapies, Inc.

3000 Pegasus Park Drive
Suite 1430
Dallas, TX 75247
United States
214 612 0000
https://www.tayshagtx.com

Sector(s): Healthcare
Industry: Biotechnology
Full-time employees: 52

Key executives

Name	Title	Pay	Exercised	Year born
Mr. Sean P. Nolan	CEO & Chairman	925.33k	N/A	1968
Dr. Sukumar Nagendran M.D.	President, Head of Research & Development and Director	820.59k	N/A	1967
Ms. Tracy M. Porter SPHR	Chief People Officer	N/A	N/A	N/A
Mr. Frederick Porter Ph.D.	Chief of Staff & Technical Operations Officer	N/A	N/A	N/A
Ms. Emily McGinnis M.P.H.	Chief Patient Advocacy & External Affairs Officer	N/A	N/A	N/A
Mr. Sean McAuliffe	Chief Business Officer	N/A	N/A	N/A
Dr. Steven Gray Ph.D.	Chief Scientific Advisor of UT Southwestern Gene Therapy Program	N/A	N/A	N/A
Berge Minassian M.D.	Chief Medical Advisor of UT Southwestern Gene Therapy Program	N/A	N/A	N/A
Ms. Rumana Haque-Ahmed	Chief Regulatory Officer	N/A	N/A	N/A
Dr. Meredith Schultz M.D., M.S.	Chief Medical Officer	N/A	N/A	N/A

Amounts are as of 31 December 2023, and compensation values are for the last fiscal year ending on that date. Pay includes salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.

Description

Taysha Gene Therapies, Inc., a gene therapy company, focuses on developing and commercializing adeno-associated virus-based gene therapies for the treatment of monogenic diseases of the central nervous system. It primarily develops TSHA-120 for the treatment of giant axonal neuropathy; TSHA-102 for the treatment of Rett syndrome; TSHA-121 for the treatment of CLN7 disease; TSHA-118 for the treatment of CLN1 disease; TSHA-105 for the treatment of for SLC13A5 deficiency; TSHA-113 for the treatment of tauopathies; TSHA-106 for the treatment of angelman syndrome; TSHA-114 for the treatment of fragile X syndrome; and TSHA-101 for the treatment of GM2 gangliosidosis. Taysha Gene Therapies, Inc. has a strategic partnership with The University of Texas Southwestern Medical Center. Taysha Gene Therapies, Inc. was incorporated in 2019 and is headquartered in Dallas, Texas.

Corporate governance

Taysha Gene Therapies, Inc.’s ISS governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder rights: N/A; Compensation: N/A.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while 10 indicates higher governance risk.